Selumetinib (AZD6244)

Name: Selumetinib (AZD6244)
Brand: Selleck Chemicals
SKU: S1008
Rating: 5 (526 reviews)

For research use only.

Catalog No.S1008 Synonyms: ARRY-142886

526 publications

Selumetinib (AZD6244) Chemical Structure

CAS No. 606143-52-6

Selumetinib (AZD6244, ARRY-142886) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Selumetinib suppresses cell proliferation, migration and trigger apoptosis. Phase 3.

Selleck's Selumetinib (AZD6244) has been cited by 526 publications

Nature, 2020, 588(7838):509-514

PubMed: 32927473 ( click the link to review the publication )

Cancer Cell, 2020, 37(1):85-103

PubMed: 31935375 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cancer Cell, 2020, 37(2):183-199

PubMed: 31978326 ( click the link to review the publication )

Nat Med, 2019, 25(1):130-140

PubMed: 30510251 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Mater, 2018, 17(4):361-368

PubMed: 29403054 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cell, 2018, 172(4):857-868

PubMed: 29336889 ( click the link to review the publication )

Nat Med, 2018, 24(7):961-967

PubMed: 29808006 ( click the link to review the publication )

Cancer Cell, 2018, 33(1):91-107

PubMed: 29316436 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):439-452

PubMed: 30205046 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):119-126

PubMed: 27870838 ( click the link to review the publication )

Gastroenterology, 2017, 152(5):1161-1173

PubMed: 27956228 ( click the link to review the publication )

Nature, 2016, 10.1038/nature19347

PubMed: 27580028 ( click the link to review the publication )

Nat Biotechnol, 2016, 34(2):184-191

PubMed: 26780180 ( click the link to review the publication )

Gastroenterology, 2016, 150(4):918-30

PubMed: 26677984 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Nat Genet, 2015, 47(9):996-1002

PubMed: 26214590 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Cancer Cell, 2015, 27(2):240-56

PubMed: 25600339 ( click the link to review the publication )
Nature, 2014, 30;514(7524):628-32.

PubMed: 25119024 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Cancer Discov, 2014, 4(10):1214-29

PubMed: 25256614 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):232-45

PubMed: 24356096 ( click the link to review the publication )

Cancer Discov, 2013, 3(3):350-62

PubMed: 23288408 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(5):414-24

PubMed: 22588879 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Nat Chem Biol, 2012, 8(11):905-912

PubMed: 23023260 ( click the link to review the publication )

Nat Genet, 2011, 44(2):133-9

PubMed: 22197931 ( click the link to review the publication )

Nat Genet, 2011, 43(11):1119-26

PubMed: 21946352 ( click the link to review the publication )

Nature, 2010, 16;468(7326):968-72.

PubMed: 21107320 ( click the link to review the publication )

Cancer Res, 2021, canres.1895.2020

PubMed: 33402388 ( click the link to review the publication )

Cancer Lett, 2021, 502:25-33

PubMed: 33440231 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):22

PubMed: 33413561 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3157

PubMed: 32572029 ( click the link to review the publication )

Eur Respir J, 2020, 8;2000522

PubMed: 32513782 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Dev Cell, 2020, 52(5):563-573

PubMed: 32032547 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(33):20004-20014

PubMed: 32747568 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202008017

PubMed: 32989154 ( click the link to review the publication )
Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancer Res, 2020, canres.0448.2020

PubMed: 32605999 ( click the link to review the publication )

Cell Rep, 2020, 31(2):107514

PubMed: 32294432 ( click the link to review the publication )

Eur J Cancer, 2020, 144:17-30

PubMed: 33316635 ( click the link to review the publication )

Oncogene, 2020, 14

PubMed: 32291414 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )

Oncogene, 2020, 39(15):3218-3225

PubMed: 32051554 ( click the link to review the publication )

Oncogene, 2020, 39(3):703-717

PubMed: 31541192 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2586

PubMed: 32927828 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(7):E1744

PubMed: 32629964 ( click the link to review the publication )

PLoS Pathog, 2020, 16(2):e1008307

PubMed: 32069328 ( click the link to review the publication )

Cell Death Dis, 2020, 29;11(5):406

PubMed: 32471991 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202000657R

PubMed: 33124742 ( click the link to review the publication )

Front Immunol, 2020, 14;11:867

PubMed: 32477351 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0706

PubMed: 33208393 ( click the link to review the publication )

Development, 2020, 147(23)dev192351

PubMed: 33144395 ( click the link to review the publication )

Mol Cancer Ther, 2020, 13;molcanther11722019

PubMed: 32404410 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-20-0664

PubMed: 33106373 ( click the link to review the publication )
Front Oncol, 2020, 10:1482

PubMed: 33042794 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(20)E7649

PubMed: 33081092 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):21985

PubMed: 33319783 ( click the link to review the publication )

J Biol Chem, 2020, 30 pii: jbc

PubMed: 32358059 ( click the link to review the publication )

Cancer Commun (Lond), 2020, 10.1002/cac2.12092

PubMed: 32888253 ( click the link to review the publication )

J Ethnopharmacol, 2020, 251:112535

PubMed: 31926315 ( click the link to review the publication )

Chem Biol Interact, 2020, 315:108910

PubMed: 31790661 ( click the link to review the publication )

Transl Oncol, 2020, 14(1):100920

PubMed: 33137541 ( click the link to review the publication )

Eur J Pharmacol, 2020, 870:172821

PubMed: 31770526 ( click the link to review the publication )

Pediatr Blood Cancer, 2020, e28639

PubMed: 32975370 ( click the link to review the publication )

Pathol Oncol Res, 2020, 10.1007/s12253-020-00834-y

PubMed: 32591993 ( click the link to review the publication )

J Chemother, 2020, 32(8):437-444

PubMed: 33052075 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:610

PubMed: 32754596 ( click the link to review the publication )

Cell Mol Life Sci, 2020, 10.1007/s00018-020-03617-5

PubMed: 32804243 ( click the link to review the publication )

Commun Biol, 2020, 3(1):593

PubMed: 33087841 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

J Pathol, 2020, e5503

PubMed: 32613636 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, S2352-345X(20)30117-X

PubMed: 32771388 ( click the link to review the publication )

Nat Chem Biol, 2020, 10.1038/s41589-020-0609-7

PubMed: 32778845 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12673

PubMed: 32191822 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )
Clin Cancer Res, 2020, 10.1158

PubMed: 32034077 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):387-402

PubMed: 32142667 ( click the link to review the publication )

Viruses, 2020, 12(10)E1128

PubMed: 33028008 ( click the link to review the publication )

Arch Virol, 2020, 10.1007/s00705-020-04524-7

PubMed: 31942645 ( click the link to review the publication )

Gastroenterology, 2019, 157(3):823-837

PubMed: 31078621 ( click the link to review the publication )

Gastroenterology, 2019, 156(3):577-581

PubMed: 30391471 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

J Clin Invest, 2019, 10.1172/JCI128678

PubMed: 31805013 ( click the link to review the publication )

Nat Commun, 2019, 10(1-:2987

PubMed: 31278260 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5549

PubMed: 31804471 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2919

PubMed: 31266962 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-4145

PubMed: 31285371 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Dev Cell, 2019, 51(5):602-616.e12

PubMed: 31794718 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2494-2510

PubMed: 30862719 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Rep, 2019, 27(3):806-819

PubMed: 30995478 ( click the link to review the publication )

Cell Rep, 2019, 29(1):118-134

PubMed: 31577942 ( click the link to review the publication )

Thyroid, 2019, 29(1):79-92

PubMed: 30398411 ( click the link to review the publication )

Redox Biol, 2019, 24:101189

PubMed: 30986607 ( click the link to review the publication )

Oncogene, 2019, 38(18):3402-3414

PubMed: 30643193 ( click the link to review the publication )
Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )

EBioMedicine, 2019, 49:106-117

PubMed: 31668570 ( click the link to review the publication )

Stem Cell Reports, 2019,

PubMed: 31231022 ( click the link to review the publication )

Cancer Lett, 2019, 442:53-67

PubMed: 30391781 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):83

PubMed: 30770740 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 18;38(1):85

PubMed: 30777101 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31652979 ( click the link to review the publication )

PLoS Pathog, 2019,

PubMed: 30716130 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12812

PubMed: 31323160 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 32(2):280-291

PubMed: 30277012 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):871

PubMed: 31740667 ( click the link to review the publication )

Br J Cancer, 2019, 121(9):758-767

PubMed: 31551581 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31766464 ( click the link to review the publication )

Cells, 2019, 8(8)

PubMed: 31409052 ( click the link to review the publication )

PLoS Genet, 2019, 15(4):e1008077

PubMed: 30969964 ( click the link to review the publication )

Front Immunol, 2019, 10:2020

PubMed: 31507609 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Mol Oncol, 2019, 13(7):1467-1489

PubMed: 30919591 ( click the link to review the publication )

Cancer Sci, 2019, 110(8):2529-2539

PubMed: 31119819 ( click the link to review the publication )

Oncogenesis, 2019, 8(9):50

PubMed: 31492847 ( click the link to review the publication )

Transl Psychiatry, 2019, 9(1):306

PubMed: 31740729 ( click the link to review the publication )

Lab Invest, 2019, 10.1038/s41374-019-0274-1

PubMed: 31201369 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )
Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13308

PubMed: 31527768 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7779

PubMed: 31123282 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2019, 316(1):L20-L34

PubMed: 30260287 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0268-y

PubMed: 31316177 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(1):36-46

PubMed: 31048548 ( click the link to review the publication )

Mol Carcinog, 2019, 10.1002/mc.23123

PubMed: 31571292 ( click the link to review the publication )

Front Pharmacol, 2019, 10:1159

PubMed: 31649535 ( click the link to review the publication )

Int J Oncol, 2019, 54(3):1123-1133

PubMed: 30747223 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00795-3

PubMed: 31124056 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(1):349-357

PubMed: 30682205 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Cell Cycle, 2019, 18(13):1513-1522

PubMed: 31135266 ( click the link to review the publication )

Cell Cycle, 2019, 18(5):596-604

PubMed: 30724698 ( click the link to review the publication )

J Mol Endocrinol, 2019, 63(3):199-213

PubMed: 31416049 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(8):1015-1025

PubMed: 31141756 ( click the link to review the publication )

Pathol Oncol Res, 2019, 25(2):769-775

PubMed: 30706361 ( click the link to review the publication )

Oncol Lett, 2019, 17(3):3569-3575

PubMed: 30867799 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3785-3793

PubMed: 31262905 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )

JCI Insight, 2019, 4(4)

PubMed: 30830869 ( click the link to review the publication )

Br J Cancer, 2019, 10.1038/s41416-019-0673-5

PubMed: 31839677 ( click the link to review the publication )
Transl Oncol, 2019, 13(2):201-211

PubMed: 31865182 ( click the link to review the publication )

Oncotarget, 2019, 10(14):1440-1457

PubMed: 30858928 ( click the link to review the publication )

Oncotarget, 2019, 10(56):5755-5767

PubMed: 31645898 ( click the link to review the publication )

Heliyon, 2019, 6(1):e03031

PubMed: 31909243 ( click the link to review the publication )

Sci Transl Med, 2018, 10(450)

PubMed: 30021885 ( click the link to review the publication )

Cell Res, 2018, 28(7):719-729

PubMed: 29795445 ( click the link to review the publication )

Mol Cell, 2018, 70(5):949-960

PubMed: 29861159 ( click the link to review the publication )

Mol Psychiatry, 2018, 23(2):444-458

PubMed: 28070119 ( click the link to review the publication )

Nat Commun, 2018, 9(1):579

PubMed: 29422527 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5416

PubMed: 30575746 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

Nat Commun, 2018, 9(1):28

PubMed: 29295999 ( click the link to review the publication )

J Exp Med, 2018, 215(6):1693-1708

PubMed: 29769248 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(19):4854-4864

PubMed: 29945997 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6367-6382

PubMed: 30135148 ( click the link to review the publication )

PLoS Biol, 2018,

PubMed: 30261040 ( click the link to review the publication )

Genome Med, 2018, 10(1):90

PubMed: 30482246 ( click the link to review the publication )

Biomaterials, 2018, 156:258-273

PubMed: 29222974 ( click the link to review the publication )

Theranostics, 2018, 8(5):1256-1269

PubMed: 29507618 ( click the link to review the publication )

Theranostics, 2018, 8(8):2134-2146

PubMed: 29721068 ( click the link to review the publication )

Cancer Res, 2018, 78(6):1444-1456

PubMed: 29321164 ( click the link to review the publication )

Int J Cancer, 2018, 142(2):381-391

PubMed: 28921565 ( click the link to review the publication )

Oncogene, 2018, 37(39):5340-5354

PubMed: 29858603 ( click the link to review the publication )
Cancer Lett, 2018, 414:268-277

PubMed: 29179997 ( click the link to review the publication )

Cancers (Basel), 2018, 10(11)

PubMed: 30373214 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1052

PubMed: 30323190 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Br J Cancer, 2018, 119(6):713-723

PubMed: 30116025 ( click the link to review the publication )

J Clin Med, 2018, 7(5)

PubMed: 29762469 ( click the link to review the publication )

Cancer Discov, 2018, 8(10):1237-1249

PubMed: 30045908 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 49(4):1499-1511

PubMed: 30205377 ( click the link to review the publication )

Bioinformatics, 2018, 34(17):i997-i1004

PubMed: 30423075 ( click the link to review the publication )

Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11-:2329-2340

PubMed: 30166401 ( click the link to review the publication )

Br J Haematol, 2018, 182(6):921-924

PubMed: 28771685 ( click the link to review the publication )

Cancer Sci, 2018, 109(12):3816-3825

PubMed: 30343534 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 30018229 ( click the link to review the publication )

Sci Rep, 2018, 8(1):850

PubMed: 29339801 ( click the link to review the publication )

Sci Rep, 2018,

PubMed: 29849102 ( click the link to review the publication )

J Biol Chem, 2018, 293(23):9113-9123

PubMed: 29540478 ( click the link to review the publication )

Front Pharmacol, 2018, 8:988

PubMed: 29379440 ( click the link to review the publication )

Mol Cell Endocrinol, 2018, 474:20-34

PubMed: 29428395 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )
Cell Signal, 2018, 42:11-20

PubMed: 28986121 ( click the link to review the publication )

Am J Physiol, Cell Physiol, 2018,

PubMed: 30257106 ( click the link to review the publication )

Cell Cycle, 2018, 17(4):428-438

PubMed: 29468929 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Med Sci Monit, 2018, 24:8048-8055

PubMed: 30414267 ( click the link to review the publication )

Med Sci Monit, 2018, 24:3002-3010

PubMed: 29737325 ( click the link to review the publication )

Exp Lung Res, 2018, 44(7):332-343

PubMed: 30676129 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):326-334

PubMed: 29928418 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Nat Methods, 2018, 15(9):732-740

PubMed: 30127506 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):31

PubMed: 29348467 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):542

PubMed: 29739364 ( click the link to review the publication )

Cancer Discov, 2018, 8(11):1458-1473

PubMed: 30185628 ( click the link to review the publication )

Oncotarget, 2018, 9(74):33995-34008

PubMed: 30338041 ( click the link to review the publication )

Gut, 2017, 66(6):1106-1115

PubMed: 27670374 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2081-2090

PubMed: 28504649 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(21):6567-6579

PubMed: 28765329 ( click the link to review the publication )

Neuro Oncol, 2017, 20(6):764-775

PubMed: 29136244 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

Int J Cancer, 2017, 140(12):2758-2770

PubMed: 27813079 ( click the link to review the publication )

Cancer Lett, 2017, 408:130-137

PubMed: 28866094 ( click the link to review the publication )

Br J Cancer, 2017, 116(8):1065-1076

PubMed: 28301874 ( click the link to review the publication )
Cancer Discov, 2017, 7(4):369-379

PubMed: 28122867 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

Sci Rep, 2017, 7:44123

PubMed: 28276530 ( click the link to review the publication )

J Steroid Biochem Mol Biol, 2017, 165(Pt B):258-267

PubMed: 27369115 ( click the link to review the publication )

J Biol Chem, 2017, 292(10):3970-3976

PubMed: 28179426 ( click the link to review the publication )

Urol Oncol, 2017, 35(1):32

PubMed: 27692847 ( click the link to review the publication )

Front Physiol, 2017, 7:682

PubMed: 28149280 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 85:149-158

PubMed: 28254430 ( click the link to review the publication )

Melanoma Res, 2017, 27(6):545-557

PubMed: 29076949 ( click the link to review the publication )

PLoS One, 2017, 12(9):e0184861

PubMed: 28910386 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0170445

PubMed: 28118392 ( click the link to review the publication )

Am J Reprod Immunol, 2017, 78(4)

PubMed: 28635072 ( click the link to review the publication )

ACS Omega, 2017, 2(11):7868-7880

PubMed: 30023564 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Anticancer Res, 2017, 37(2):607-614

PubMed: 28179307 ( click the link to review the publication )

Biotechnol Lett, 2017, 39(7):1069-1077

PubMed: 28353145 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13174-13185

PubMed: 28061458 ( click the link to review the publication )

JCI Insight, 2017, 2(3):e89473

PubMed: 28194436 ( click the link to review the publication )

Oncotarget, 2017, 8(61):104193-104205

PubMed: 29262632 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90037-90049

PubMed: 29163809 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )

Oncotarget, 2017, 8(22):36628-36638

PubMed: 28410230 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94606-94618

PubMed: 29212253 ( click the link to review the publication )
Oncotarget, 2017, 8(18):30151-30161

PubMed: 28404914 ( click the link to review the publication )

Oncotarget, 2017, 9(5):5529-5544

PubMed: 29464016 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28938614 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13174-13185

PubMed: 28061458 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29113345 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90037-90049

PubMed: 29163809 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11460-11479

PubMed: 28002790 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Cell, 2017, 168(5):890-903

PubMed: 28162770 ( click the link to review the publication )

J Exp Med, 2017, 214(6):1691-1710

PubMed: 28450382 ( click the link to review the publication )

Oncotarget, 2017, 8(49):84697-84713

PubMed: 29156677 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Melanoma Res, 2017, 27(6):545-557

PubMed: 29076949 ( click the link to review the publication )

JCI Insight, 2017, 2(3):e89473

PubMed: 28194436 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3815-3829

PubMed: 29423085 ( click the link to review the publication )

Oncotarget, 2017, 8(22):36628-36638

PubMed: 28410230 ( click the link to review the publication )

Oncotarget, 2017, 8(18):30151-30161

PubMed: 28404914 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(1):349-64

PubMed: 26657862 ( click the link to review the publication )

Nat Commun, 2016, 7:13615

PubMed: 27897178 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2987

PubMed: 27185371 ( click the link to review the publication )
Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(24):6021-6030

PubMed: 27259561 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Cancer Res, 2016, 76(3):675-85

PubMed: 26676756 ( click the link to review the publication )

Cancer Res, 2016, 76(20):6095-6106

PubMed: 27569217 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.11414

PubMed: 26999821 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

J Invest Dermatol, 2016, 136(12):2475-2484

PubMed: 27498344 ( click the link to review the publication )

Cancers (Basel), 2016,

PubMed: 27187477 ( click the link to review the publication )

Cell Death Dis, 2016, 7(10):e2432

PubMed: 27787516 ( click the link to review the publication )

Cell Chem Biol, 2016, 23(12):1550-1559

PubMed: 27939899 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1460-71

PubMed: 27196754 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(3):1139-50

PubMed: 26933192 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(12):1204-1216

PubMed: 27655129 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Mol Cancer Res, 2016,

PubMed: 26582713 ( click the link to review the publication )

Sci Rep, 2016, 6:26803

PubMed: 27222248 ( click the link to review the publication )

Sci Rep, 2016,

PubMed: 27412232 ( click the link to review the publication )

J Biol Chem, 2016, 291(41):21694-21702

PubMed: 27576686 ( click the link to review the publication )

BMC Genomics, 2016, 17(1):723

PubMed: 27613601 ( click the link to review the publication )

Int J Oncol, 2016, 49(3):953-60

PubMed: 27572939 ( click the link to review the publication )

Biochemistry, 2016, 10.1172/JCI81468

PubMed: 26974155 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0147682

PubMed: 26821351 ( click the link to review the publication )
PLoS One, 2016, 11(9):e0162634

PubMed: 27611696 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155893

PubMed: 27196001 ( click the link to review the publication )

Thorac Cancer, 2016, 7(3):279-87

PubMed: 27148412 ( click the link to review the publication )

PeerJ, 2016, 4:e1683

PubMed: 26893968 ( click the link to review the publication )

Leuk Res, 2016, 50:1-10

PubMed: 27626202 ( click the link to review the publication )

Methods Enzymol, 2016, 568:557-80

PubMed: 26795484 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26936993 ( click the link to review the publication )

Oncotarget, 2016, 7(2):1598-607

PubMed: 26624982 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9102-17

PubMed: 26802022 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65147-65156

PubMed: 27556501 ( click the link to review the publication )

Integr Biol, 2016, 8(1):73-90

PubMed: 26658688 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7960-9

PubMed: 26799289 ( click the link to review the publication )

Oncotarget, 2016, 7(31):49597-49610

PubMed: 27391062 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19575-88

PubMed: 26988909 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):172-83

PubMed: 26487278 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9102-17

PubMed: 26802022 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30907-23

PubMed: 27127178 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27150057 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65147-65156

PubMed: 27556501 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(48):78396-78411

PubMed: 27623078 ( click the link to review the publication )
Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27174919 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.30

PubMed: 25753158 ( click the link to review the publication )

Nat Commun, 2015, 6:8583

PubMed: 26456302 ( click the link to review the publication )

Nat Commun, 2015, 6:7769

PubMed: 26183061 ( click the link to review the publication )

J Natl Cancer Inst, 2015, 108(6):djv406

PubMed: 26719346 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0013

PubMed: 26034127 ( click the link to review the publication )

Leukemia, 2015, 29(3):705-14

PubMed: 25102946 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(32):9990-5

PubMed: 26216950 ( click the link to review the publication )

Neuro Oncol, 2015, 10.1093/neuonc/nou369

PubMed: 25712957 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-15-0370

PubMed: 25952648 ( click the link to review the publication )

Cancer Res, 2015, 75(5):880-91

PubMed: 25432174 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.97

PubMed: 25867065 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.12

PubMed: 25684139 ( click the link to review the publication )

Cancer Lett, 2015, 364(1):70-8

PubMed: 25937299 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(7):1863-1872

PubMed: 25789707 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 28(5):572-89

PubMed: 26112748 ( click the link to review the publication )

J Neurosci, 2015, 35(3):972-84

PubMed: 25609615 ( click the link to review the publication )

J Neurosci, 2015, 35(7):3034-47

PubMed: 25698741 ( click the link to review the publication )

FASEB J, 2015, 10.1096/fj.14-267278

PubMed: 25857555 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2831-9

PubMed: 26438159 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-14-0810

PubMed: 25777962 ( click the link to review the publication )
Mol Oncol, 2015, 9(7):1434-46

PubMed: 25933688 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

J Cancer, 2015, 6(12):1195-205

PubMed: 26535060 ( click the link to review the publication )

Gynecol Oncol, 2015, 139(1):118-26

PubMed: 26232337 ( click the link to review the publication )

Gynecol Oncol, 2015, 138(1):165-73

PubMed: 25933683 ( click the link to review the publication )

Front Oncol, 2015, 5:135

PubMed: 26137449 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Transl Med, 2015, 13:210

PubMed: 26139106 ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2014.12.007

PubMed: 25624003 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2015, 308(10):E899-911

PubMed: 25805192 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Biochem J, 2015, 465(2):227-38

PubMed: 25353634 ( click the link to review the publication )

Respir Res, 2015, 16:48

PubMed: 25890309 ( click the link to review the publication )

Int J Oncol, 2015, 47(3):849-56

PubMed: 26179332 ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

Cell Signal, 2015, 27(10):1939-48

PubMed: 26163823 ( click the link to review the publication )

Prostate, 2015, 10.1002/pros.22945

PubMed: 25560638 ( click the link to review the publication )

Exp Cell Res, 2015, 332(1):1-10

PubMed: 25637219 ( click the link to review the publication )

BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

Radiat Oncol, 2015, 10:214

PubMed: 26498922 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0137917

PubMed: 26360058 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 456(3):821-6

PubMed: 25498501 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.01.012

PubMed: 25615947 ( click the link to review the publication )
Oncotarget, 2015,

PubMed: 26036637 ( click the link to review the publication )

Oncotarget, 2015, 6(5):3165-77

PubMed: 25638158 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33623-35

PubMed: 26378038 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17491-500

PubMed: 26036637 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Oncotarget, 2015, 6(16):14472-87

PubMed: 25961376 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33397-409

PubMed: 26397223 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26544513 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33623-35

PubMed: 26378038 ( click the link to review the publication )

Cell, 2015, 162(6):1271-85

PubMed: 26359985 ( click the link to review the publication )

EMBO Mol Med, 2015, 7(9):1104-18

PubMed: 26105199 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8698-708

PubMed: 25826088 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26317790 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(7):1863-1872

PubMed: 25789707 ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )

Nano Lett, 2015, 15(12):8032-43

PubMed: 26540670 ( click the link to review the publication )

Blood, 2014, 27;124(23):3420-30

PubMed: 25253770 ( click the link to review the publication )

Nat Commun, 2014, 5:3901

PubMed: 24849047 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(8):5083-96

PubMed: 24526220 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(23):6023-33

PubMed: 25316819 ( click the link to review the publication )

Leukemia, 2014, 10.1038/leu.2014.187.

PubMed: 24912431 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2825-34

PubMed: 24648348 ( click the link to review the publication )
Cancer Res, 2014, 74(20):5866-77

PubMed: 25168481 ( click the link to review the publication )

Oncogene, 2014, 33(33):4236-41

PubMed: 24469055 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.392

PubMed: 25435367 ( click the link to review the publication )

J Invest Dermatol, 2014, 134(2):366-73

PubMed: 23924903 ( click the link to review the publication )

Sci Signal, 2014, 7(311):ra12

PubMed: 24497609 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(3):479-84

PubMed: 24422853 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

FASEB J, 2014, 10.1096/fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(2):353-63

PubMed: 24398428 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(7):1894-906

PubMed: 24825855 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-14-0452

PubMed: 25349308 ( click the link to review the publication )

Endocr Relat Cancer, 2014, 21(2):161-73

PubMed: 24243688 ( click the link to review the publication )

Mol Nutr Food Res, 2014, 58(3):528-36

PubMed: 24039193 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Hum Mol Genet, 2014, 23(1):1-11

PubMed: 23933734 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(10):1509-19

PubMed: 24962318 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4088-103

PubMed: 25182533 ( click the link to review the publication )

Neuroscience, 2014, 562:69-74

PubMed: 24412130 ( click the link to review the publication )

Virology, 2014, 468-470C:490-503

PubMed: 25261871 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(9):1239-47

PubMed: 24971884 ( click the link to review the publication )

Exp Cell Res, 2014, 327(2):340-52

PubMed: 25128814 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: 25426675 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )
BMC Cancer, 2014, 14(1):240

PubMed: 24708867 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2014, 73(2):259-70

PubMed: 24253175 ( click the link to review the publication )

PLoS One, 2014, 9(2):e83957

PubMed: 24551032 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115068

PubMed: 25500581 ( click the link to review the publication )

PLoS One, 2014, 9(10):e110306

PubMed: 25330306 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97938

PubMed: 24835245 ( click the link to review the publication )

PLoS One, 2014, 9(2):e89646

PubMed: 24586933 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(4):958-61

PubMed: 25218145 ( click the link to review the publication )

Radiat Res, 2014, 182(3):350-62

PubMed: 25117621 ( click the link to review the publication )

Sensors (Basel), 2014, 14(3):5074-117

PubMed: 24625737 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 24962990 ( click the link to review the publication )

Mol Cancer, 2014, 13:154

PubMed: 24941944 ( click the link to review the publication )

Tumor Biol, 2014, 35(10):9759-67

PubMed: 24972969 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )

Blood, 2013, 121(23):4617-26

PubMed: 23575444 ( click the link to review the publication )

Blood, 2013, 121(19):3879-88, S1-8

PubMed: 23460614 ( click the link to review the publication )

Hepatology, 2013, 59(4):1435-47

PubMed: 24242874 ( click the link to review the publication )

J Clin Invest, 2013, 124(1):156-68

PubMed: 24316974 ( click the link to review the publication )

J Clin Invest, 2013, 123(6):2551-63

PubMed: 23635776 ( click the link to review the publication )

J Clin Invest, 2013, 123(5):2155-68

PubMed: 23543055 ( click the link to review the publication )

J Natl Cancer Inst, 2013, 105(1):33-46

PubMed: 23250956 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )
Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(1):118-27

PubMed: 23091117 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 10.1038/onc.2013.389

PubMed: 24096476 ( click the link to review the publication )

Cancer Res, 2013, 73(23):7101-10

PubMed: 24121492 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6346-58

PubMed: 23966295 ( click the link to review the publication )

Mol Syst Biol, 2013,

PubMed: 23752269 ( click the link to review the publication )

Cell Rep, 2013, 4(6):1090-9

PubMed: 24055054 ( click the link to review the publication )

Oncogene, 2013, 33(33):4236-41

PubMed: 24336323 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Sci Signal, 2013, 5(206):ra3

PubMed: 22234612 ( click the link to review the publication )

Sci Signal, 2013,

PubMed: 23532334 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):509-17

PubMed: 23490205 ( click the link to review the publication )

J Neurosci, 2013, 33(10):4280-94

PubMed: 23467345 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

Cancer Discov, 2013, 3(4):444-57

PubMed: 23358651 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(6):1131-9

PubMed: 23515613 ( click the link to review the publication )

J Mol Cell Cardiol, 2013, 59:139-47

PubMed: 23510923 ( click the link to review the publication )

Carcinogenesis, 2013, 34(3):638-46

PubMed: 23172668 ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Skelet Muscle, 2013, 3(1):17

PubMed: 23815988 ( click the link to review the publication )

Exp Cell Res, 2013, 319(12):1732-43

PubMed: 23701950 ( click the link to review the publication )

Cell Cycle, 2013, 12(13):2073-83

PubMed: 23759592 ( click the link to review the publication )

Oncol Rep, 2013, 29(2):812-8

PubMed: 23229346 ( click the link to review the publication )
PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )

PLoS One, 2013, 500(7461):222-6

PubMed: 24349570 ( click the link to review the publication )

PLoS One, 2013, 8(7):e68817

PubMed: 23935891 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )

Oncotarget, 2013, 4(9):1496-506

PubMed: 24036604 ( click the link to review the publication )

University of Southampton, 2013, University of Southampton

PubMed: ( click the link to review the publication )

Nature, 2013, 504(7478):138-42

PubMed: 24185007 ( click the link to review the publication )

Cancer Res, 2013, 73(15):4840-51

PubMed: 23737487 ( click the link to review the publication )

Gut, 2012, 61(2):202-13

PubMed: 21813469 ( click the link to review the publication )

J Clin Invest, 2012, 122(7):2637-51

PubMed: 22653055 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Oncogene, 2012, 31(27):3277-86

PubMed: 22020336 ( click the link to review the publication )

Cancer Lett, 2012, 316(1):77-84

PubMed: 22082529 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

Cardiovasc Res, 2012, 93(2):311-9

PubMed: 22068161 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(2):317-28

PubMed: 22188813 ( click the link to review the publication )

Endocr Relat Cancer, 2012, 19(1):29-38

PubMed: 22109971 ( click the link to review the publication )

Carcinogenesis, 2012, 33(5):956-61

PubMed: 22327936 ( click the link to review the publication )

Am J Pathol, 2012, 180(6):2462-78

PubMed: 22546478 ( click the link to review the publication )

J Biol Chem, 2012, 287(50):41797-807

PubMed: 23076151 ( click the link to review the publication )

Surgery, 2012, 152(6):1142-9

PubMed: 23158184 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2012, 304(5):C431-9

PubMed: 23255578 ( click the link to review the publication )

Neuroscience, 2012, 206:224-36

PubMed: 22280975 ( click the link to review the publication )
Cancer Biol Ther, 2012, 13(1):43-9

PubMed: 22336587 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(1):e29622

PubMed: 22253748 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

Aging, 2012, 4(11):803-822

PubMed: 23362510 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Biomaterials, 2011, 32(35):9197-206

PubMed: 21899882 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:489

PubMed: 21613978 ( click the link to review the publication )

J Invest Dermatol, 2011, 132(2):356-64

PubMed: 21993556 ( click the link to review the publication )

J Clin Endocrinol Metab, 2011, 97(2):E173-82

PubMed: 22090271 ( click the link to review the publication )

Mol Cancer Res, 2011, 9(5):545-52

PubMed: 21478267 ( click the link to review the publication )

Endocrinology, 2011, 152(7):2589-98

PubMed: 21521747 ( click the link to review the publication )

Mol Endocrinol, 2011, 25(12):2041-53

PubMed: 22053001 ( click the link to review the publication )

Cancer Biol Ther, 2011, 12(3):215-28

PubMed: 21642769 ( click the link to review the publication )

Biol Reprod, 2011, 85(1):42-50

PubMed: 21349822 ( click the link to review the publication )

PLoS One, 2011, 6(12):e28973

PubMed: 22194965 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Brit J Haematol, 2010, 149(4):537-49

PubMed: 20331454 ( click the link to review the publication )

Methods Mol Biol, 2010, 661:107-22

PubMed: 20811979 ( click the link to review the publication )

Nature, 2010, 468(7326):973-7

PubMed: 21107323 ( click the link to review the publication )

P Natl Acad Sci USA, 2009, 106(48):20411-6

PubMed: 19915144 ( click the link to review the publication )

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description

Features

First MEK inhibitor being tested in Phase II clinical trials.

Targets

MEK1 ^[1] (Cell-free assay)	MEK1 ^[13] (Cell-free assay)	MEK2 ^[13] (Cell-free assay)
14 nM	99 nM(Kd)	530 nM(Kd)

In vitro

AZD6244 is not competitive with ATP and inactivates the ERK1/2 phosphorylation with IC50 concentrations below 40 nM. AZD6244 also inhibits the growth of primary HCC cells through inhibition of ERK1/2 and p90^RSK phosphorylation, accompanied with elevation of the cleavage of caspase-3 and caspase-7, and cleaved poly(ADP)ribose polymerase. AZD6244 has little effects on the p38, c-Jun-NH₂-kinase, phosphatidylinositol 3-kinase, and MEK5/ERK5 pathways. ^[1] AZD6244 is sensitive to Raf mutations in breast cancer cell lines and Ras mutations in NSCLC cell lines. ^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
CHP-212	NIHK[4lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NIrJd2VKdmirYnn0bY9vKG:oIHj1cYFvKEOKUD2yNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMECzNVU{KM7:TT6=	M3:zW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
H9	M3LXOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3PSfmlvcGmkaYTpc44hd2ZiaIXtZY4hUDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IECuNFIzQDhizszNMi=>	M2XOZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HL-60	M{DhXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4rDR2lvcGmkaYTpc44hd2ZiaIXtZY4hUExvNkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvODJ2NUmg{txONg>?	NEnnPHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NOMO-1	MonzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2jneGlvcGmkaYTpc44hd2ZiaIXtZY4hVk:PTz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjB\|MUm3JO69VS5?	Mk[yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
DU-4475	M3HRVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NF7LSWhKdmirYnn0bY9vKG:oIHj1cYFvKESXLUS0O\|Uh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMEOzOlch\|ryPLh?=	NHfwSYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
M14	M{LyPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NE[3fodKdmirYnn0bY9vKG:oIHj1cYFvKE1zNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4xOzZ6OTFOwG0v	M371VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HT-144	M4flTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWrJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTF2NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4xQDlyNTFOwG0v	NESwfZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SK-N-AS	MlH0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNU5vQWOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvODl{OEOg{txONg>?	NE\HZ3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
LB2518-MEL	M4LDVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYTFUXFRUW6qaXLpeIlwdiCxZjDoeY1idiCOQkK1NVguVUWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlA6Ozh{IN88UU4>	NW\QN3pZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
C32	M4XZNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVzL[olIUW6qaXLpeIlwdiCxZjDoeY1idiCFM{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvODl6MkOg{txONg>?	NWnq[pg5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
BHT-101	M16wdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{nyUGlvcGmkaYTpc44hd2ZiaIXtZY4hSkiWLUGwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5zME[5N{DPxE1w	Mmr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
KY821	M2PFc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGnMdFdKdmirYnn0bY9vKG:oIHj1cYFvKEu\OEKxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjFyN{G4JO69VS5?	MnPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
CP50-MEL-B	MkHkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEK1TYhKdmirYnn0bY9vKG:oIHj1cYFvKEOSNUCtUWVNNUJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IECuNVI4QTRizszNMi=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
MEL-HO	NU\GPIh3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFTQWGxKdmirYnn0bY9vKG:oIHj1cYFvKE2HTD3IU{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5zM{i4OEDPxE1w	MnHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
EoL-1-cell	NV7MdGIxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYPJcohq[mm2aX;uJI9nKGi3bXHuJGVwVC1zLXPlcIwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMUS0O\|Yh\|ryPLh?=	MmnQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
DOK	MkXyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYnJcohq[mm2aX;uJI9nKGi3bXHuJGRQUyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD6xOFcxQCEQvF2u	NX7VW3dGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SH-4	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkeyTY5pcWKrdHnvckBw\iCqdX3hckBUUC12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlE3PjR6IN88UU4>	MkXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
BPH-1	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2TRZmlvcGmkaYTpc44hd2ZiaIXtZY4hSlCKLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOTh{M{Gg{txONg>?	NHTzXFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HuP-T4	NUHTPHYxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHf3fldKdmirYnn0bY9vKG:oIHj1cYFvKEi3UD3UOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5zOUWzNkDPxE1w	Moj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
KU812	NEfLT5VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUjJcohq[mm2aX;uJI9nKGi3bXHuJGtWQDF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlIyOTZ6IN88UU4>	M1XV[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
A549	NHr4PFVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXPtdIMyUW6qaXLpeIlwdiCxZjDoeY1idiCDNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjJzNEGzJO69VS5?	NIfFZWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HTC-C3	M4rPNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2XFWGlvcGmkaYTpc44hd2ZiaIXtZY4hUFSFLVOzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjJzNE[xJO69VS5?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
A101D	NUnNd2cxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXHJcohq[mm2aX;uJI9nKGi3bXHuJGEyODGGIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlI1ODN\|IN88UU4>	NUDwXpBpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
ONS-76	NFP5UW9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MX7Jcohq[mm2aX;uJI9nKGi3bXHuJG9PWy15NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4zPDR3MzFOwG0v	NWXDS5luRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
RKO	NVjp[o1vT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlfETY5pcWKrdHnvckBw\iCqdX3hckBTU09iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IECuNlQ5OzhizszNMi=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
WM-115	NFnqV49Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnLzTY5pcWKrdHnvckBw\iCqdX3hckBYVS1zMUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOjZ5NUSg{txONg>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HCC2998	NXnOR4JbT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NF74VXZKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{K5PVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMk[5NFch\|ryPLh?=	NGXJUoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
C2BBe1	MmjjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mke1TY5pcWKrdHnvckBw\iCqdX3hckBEOkKEZUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOjd{NUmg{txONg>?	NWTlbnc1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
RVH-421	NFHqW25Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVjEVpBGUW6qaXLpeIlwdiCxZjDoeY1idiCUVlitOFIyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLkK3PVM6KM7:TT6=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
H-EMC-SS	NYL1VFhXT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGguTU2FLWPTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjJ7MEm5JO69VS5?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
ML-2	M{XyZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M37RPGlvcGmkaYTpc44hd2ZiaIXtZY4hVUxvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4zQTN4MzFOwG0v	MmHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SW620	NGLRT4dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NIDWbYpKdmirYnn0bY9vKG:oIHj1cYFvKFOZNkKwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjNyMkKg{txONg>?	MnHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
UACC-257	M3W4Umdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mkm4TY5pcWKrdHnvckBw\iCqdX3hckBWSUOFLUK1O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5\|MkG4OEDPxE1w	M4HBNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
AsPC-1	NFLOVmdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmjhTY5pcWKrdHnvckBw\iCqdX3hckBCe1CFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOzJ2M{mg{txONg>?	MnvDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
CAL-39	MofUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkHITY5pcWKrdHnvckBw\iCqdX3hckBESUxvM{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOzN{Mk[g{txONg>?	Ml;oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
COLO-679	NGX5O5JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnznTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[3PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5\|NEGxPUDPxE1w	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H747	MkjvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1vqR2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3OFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwM{WwPVgh\|ryPLh?=	M37we\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H1437	M2W1Omdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MX\Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUSzO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5\|NUK4OUDPxE1w	MmH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
PSN1	NX;6fYtrT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MoHMTY5pcWKrdHnvckBw\iCqdX3hckBRW05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlM3PjB7IN88UU4>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NKM-1	NFfKNoxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEf0O2lKdmirYnn0bY9vKG:oIHj1cYFvKE6NTT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjN6NUig{txONg>?	MnfRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MZ2-MEL	MoCxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlPmTY5pcWKrdHnvckBw\iCqdX3hckBOYjJvTVXMJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjN7NEO3JO69VS5?	Moj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SK-MEL-2	NF7jeGlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NX3nNG5sUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD60NFUxPiEQvF2u	NYH2d4Y{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
LAMA-84	MkS5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NID6b\|NKdmirYnn0bY9vKG:oIHj1cYFvKEyDTVGtPFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwNEW2NlIh\|ryPLh?=	NYrheVg6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
U-266	M3;Qcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHTWSVdKdmirYnn0bY9vKG:oIHj1cYFvKFVvMk[2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjR6N{e0JO69VS5?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
RCM-1	M4jaVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGriV3NKdmirYnn0bY9vKG:oIHj1cYFvKFKFTT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjR7M{i1JO69VS5?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
EM-2	MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NES2dWlKdmirYnn0bY9vKG:oIHj1cYFvKEWPLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvPTFzN{Wg{txONg>?	NUHoU\|VjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
Mewo	M2T1SGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXLZeopOUW6qaXLpeIlwdiCxZjDoeY1idiCPZYfvJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjV{MUCxJO69VS5?	NHu3dIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
COLO-741	MmLHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4TQT2lvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz23OFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwNUOxNVkh\|ryPLh?=	Mor6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
ACN	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEDrZ4xKdmirYnn0bY9vKG:oIHj1cYFvKEGFTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE42PjZ7IN88UU4>	M36yUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
MV-4-11	NUHnV2FLT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MV7Jcohq[mm2aX;uJI9nKGi3bXHuJG1XNTRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvPTd3NEOg{txONg>?	NXK4W4FbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SW780	NHG4SWJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFPafmhKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjZ4NkO0JO69VS5?	NXHYPGxERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
JVM-3	NVi5XZB5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVPodI1CUW6qaXLpeIlwdiCxZjDoeY1idiCMVl2tN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC55MEC2JO69VS5?	MkjyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
RPMI-8226	NFPSVlRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MoDiTY5pcWKrdHnvckBw\iCqdX3hckBTWE2LLUiyNlYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwN{Sg{txONg>?	M1PWS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HO-1-N-1	MoT3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MoX6TY5pcWKrdHnvckBw\iCqdX3hckBJVy1zLV6tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC55NEC1NkDPxE1w	M3mxT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
BV-173	MlS4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXz6[lE1UW6qaXLpeIlwdiCxZjDoeY1idiCEVj2xO\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwN{S4NFIh\|ryPLh?=	M1LvbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H2291	M1;QNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWK4bW9QUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIzQTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IECuO\|YyPzNizszNMi=>	M2rMZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SK-MEL-30	M1fLcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYXJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2zNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC55OEG3NUDPxE1w	NEXsb4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
LB2241-RCC	NH32d3NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mo[2TY5pcWKrdHnvckBw\iCqdX3hckBNSjJ{NEGtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLke4PVkyKM7:TT6=	NUPKNmM3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
LOXIMVI	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3LwTGlvcGmkaYTpc44hd2ZiaIXtZY4hVE:[SV3WTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC56NUi1OEDPxE1w	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HT-29	NEDFT\|lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml7rTY5pcWKrdHnvckBw\iCqdX3hckBJXC1{OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE45PzNzOTFOwG0v	MmXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
KG-1	MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmS3TY5pcWKrdHnvckBw\iCqdX3hckBMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlg6PTR5IN88UU4>	M3frS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SW954	MonjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1rufGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7NUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvQDl4NEWg{txONg>?	Mn7WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MIA-PaCa-2	NHfoV2lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVLJcohq[mm2aX;uJI9nKGi3bXHuJG1KSS2SYVPhMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwOEm3Olgh\|ryPLh?=	M4TYSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HCE-T	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M135TmlvcGmkaYTpc44hd2ZiaIXtZY4hUEOHLWSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvQTdzM{Gg{txONg>?	NYTLTXdLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HN	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHzC[4VKdmirYnn0bY9vKG:oIHj1cYFvKEiQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlAxOjV5IN88UU4>	M4DNW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
LCLC-97TM1	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NY\zSYUxUW6qaXLpeIlwdiCxZjDoeY1idiCOQ1zDMVk4XE1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlA{OTlzIN88UU4>	NVzIWJVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NB69	NYLhe2JST3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVjlToQyUW6qaXLpeIlwdiCxZjDoeY1idiCQQk[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjB3M{mg{txONg>?	NXHOdXM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
LoVo	Mn\MS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2CxPGlvcGmkaYTpc44hd2ZiaIXtZY4hVG:YbzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU4xPjJ\|MTFOwG0v	M1\JclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HCT-116	NW[1cllHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1LEPWlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUGxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS5yNkSzNUDPxE1w	M4PRPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
AGS	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1;IUGlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlEyQDNzIN88UU4>	NGLWe4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H292	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4LFOGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyPVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwMUG5PUDPxE1w	NEDpVmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
P12-ICHIKAWA	NV:w[nhLT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1HOUGlvcGmkaYTpc44hd2ZiaIXtZY4hWDF{LVnDTGlMSVeDIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlE2QDl7IN88UU4>	NHrmU\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
D-263MG	NITuSXZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3LENWlvcGmkaYTpc44hd2ZiaIXtZY4hTC1{NkPNS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS5zOEC5OEDPxE1w	MmLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
COLO-792	M4Hmfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkHNTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS5zOE[zJO69VS5?	NVTHNmxwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HSC-3	M37Ib2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4nNV2lvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvOTh6MkOg{txONg>?	NX7pcHN1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NUGC-3	NYrIRmQxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mle0TY5pcWKrdHnvckBw\iCqdX3hckBPXUeFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvOjB\|N{mg{txONg>?	M1vWe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SW872	NGnmSXFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlHyTY5pcWKrdHnvckBw\iCqdX3hckBUXzh5MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU4zPjh3NTFOwG0v	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HuCCT1	MkTNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFjwRXFKdmirYnn0bY9vKG:oIHj1cYFvKEi3Q1PUNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS5{OUm2JO69VS5?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
QIMR-WIL	NWXwUVNZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXuwPHVDUW6qaXLpeIlwdiCxZjDoeY1idiCTSV3SMXdKVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMT6zOFM5PCEQvF2u	M2XQPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H2087	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVjRcIFXUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxQDdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGuN\|c2OSEQvF2u	NFfoOoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
LS-513	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{PlUGlvcGmkaYTpc44hd2ZiaIXtZY4hVFNvNUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjR{MUmxJO69VS5?	NYfId5p[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
CAL-54	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGXHd2hKdmirYnn0bY9vKG:oIHj1cYFvKEODTD21OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS52OUOxOEDPxE1w	M3v1T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
A204	M2G4dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFLK[GVKdmirYnn0bY9vKG:oIHj1cYFvKEF{MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvPTF4Nkeg{txONg>?	NEPnU4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CAL-62	M{nQc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVjnOYJRUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwNUKyPVIh\|ryPLh?=	MmntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
CAL-33	NHKyS2FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVLWXHNHUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytN\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwNUS2PVQh\|ryPLh?=	NIfhTHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
COLO-678	M325XWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NE\BOYhKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tOlc5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzLk[yN\|gzKM7:TT6=	M{C2T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
MEG-01	NGrpZYVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYXnT3VxUW6qaXLpeIlwdiCxZjDoeY1idiCPRVetNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwNkK5OVkh\|ryPLh?=	M{G3cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HAL-01	NYfsfnQ4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXHxUWE6UW6qaXLpeIlwdiCxZjDoeY1idiCKQVytNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwNkm1O{DPxE1w	NHfGeoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
OAW-28	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVrJcohq[mm2aX;uJI9nKGi3bXHuJG9CXy1{ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU44PDN7NzFOwG0v	NGrnNWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-SNU-1	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mnf6TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvU17VMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwN{eyOFMh\|ryPLh?=	Mo[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
BHY	M3G2b2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUPJcohq[mm2aX;uJI9nKGi3bXHuJGJJYSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMT64NVA{PCEQvF2u	NXX2bot3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
EGI-1	M2\n[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUG0VJh5UW6qaXLpeIlwdiCxZjDoeY1idiCHR1mtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS56MkiyJO69VS5?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
BB65-RCC	NIPPWmlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXPJcohq[mm2aX;uJI9nKGi3bXHuJGJDPjVvUlPDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjh\|OEW1JO69VS5?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
GAK	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NV\QN\|g6UW6qaXLpeIlwdiCxZjDoeY1idiCJQVugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvQTB2N{Wg{txONg>?	NHrIOJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SK-MEL-3	NWnNW3hHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWnEOWljUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMT65OVA4PyEQvF2u	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
KARPAS-45	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUD1WpNYUW6qaXLpeIlwdiCxZjDoeY1idiCNQWLQRXMuPDViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEKuNFgzPDhizszNMi=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
BCPAP	NYjm[JhJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWLJcohq[mm2aX;uJI9nKGi3bXHuJGJEWEGSIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyMlEzPzRizszNMi=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
RT-112	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4exT2lvcGmkaYTpc44hd2ZiaIXtZY4hWlRvMUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzNjJ4MES2JO69VS5?	M1rQc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SK-HEP-1	NWXsbXplT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNUiHUD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzNjJ7MES4JO69VS5?	MkLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
Ca9-22	Mo[zS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGL4RWdKdmirYnn0bY9vKG:oIHj1cYFvKEOjOT2yNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOi5\|N{[2O{DPxE1w	NVjIVJpqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
OS-RC-2	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Ml\PTY5pcWKrdHnvckBw\iCqdX3hckBQWy2UQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzNjRyM{O3JO69VS5?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
BFTC-905	MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3HYPGlvcGmkaYTpc44hd2ZiaIXtZY4hSk[WQz25NFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJwNEKzNVIh\|ryPLh?=	NFmxeJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HT-1080	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1XjNWlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOi52M{CxJO69VS5?	Mlr2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HCC2218	MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYjJcohq[mm2aX;uJI9nKGi3bXHuJGhESzJ{MUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIvPDh2OEeg{txONg>?	M3ywWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
KM12	NFjQdVJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1PLemlvcGmkaYTpc44hd2ZiaIXtZY4hU01zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNk42Ozl4MTFOwG0v	MonCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NB5	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWjJcohq[mm2aX;uJI9nKGi3bXHuJG5DPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMj61OlY1OSEQvF2u	MmX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
BB30-HNC	NULBd45rT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXrJcohq[mm2aX;uJI9nKGi3bXHuJGJDOzBvSF7DJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzNjdzMkmzJO69VS5?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H460	M4LjT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWDJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNE[wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzNjhyMke0JO69VS5?	Mlr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
LAN-6	M{P4cmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Ml;sTY5pcWKrdHnvckBw\iCqdX3hckBNSU5vNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNk45Ojh4NzFOwG0v	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
EW-3	NYPEengzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MULJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEKuPVI2ODVizszNMi=>	NH;n[FU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CAL-27	NGriRZNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmPETY5pcWKrdHnvckBw\iCqdX3hckBESUxvMkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFMvODZzMUig{txONg>?	Mni0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
COR-L105	NHXZfFlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2XCVGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVyxNFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNwMUO0OlIh\|ryPLh?=	MkfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
EFO-21	M1W0NWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFzyV2FKdmirYnn0bY9vKG:oIHj1cYFvKEWITz2yNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy5zOUKyOkDPxE1w	MlXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MZ1-PC	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NW[wUI4yUW6qaXLpeIlwdiCxZjDoeY1idiCPWkGtVGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNwM{G2NFUh\|ryPLh?=	NIDrS4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
EFO-27	MkG5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2flUWlvcGmkaYTpc44hd2ZiaIXtZY4hTU[RLUK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{NjN{NkGyJO69VS5?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HPAF-II	NUi5[m41T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVfybXdNUW6qaXLpeIlwdiCxZjDoeY1idiCKUFHGMWlKKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|LkOzO\|I6KM7:TT6=	M1HtRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
KU-19-19	NH32[XBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mn3JTY5pcWKrdHnvckBw\iCqdX3hckBMXS1zOT2xPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy52MUm1NUDPxE1w	MkDnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NCI-SNU-5	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2mwO2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|Lk[xOFQ6KM7:TT6=	NY[4S3lERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
LS-123	NXrRfIpRT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3fHPWlvcGmkaYTpc44hd2ZiaIXtZY4hVFNvMUKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{NjZzOEOxJO69VS5?	M4DyWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
769-P	NV:4e25ZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MoTPTY5pcWKrdHnvckBw\iCqdX3hckA4PjlvUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN{44PDJ4IN88UU4>	M4\ScVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SJSA-1	NEfIS\|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1[xPWlvcGmkaYTpc44hd2ZiaIXtZY4hW0qVQT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{Njd6MUS2JO69VS5?	MlywQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SK-LU-1	M4PUOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUC1XVZyUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3MWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|Lki2NlMyKM7:TT6=	MojWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
A3-KAW	M3vWO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NU\QWlI2UW6qaXLpeIlwdiCxZjDoeY1idiCDMz3LRXch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNwOUGwOVUh\|ryPLh?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
LB996-RCC	M1:3c2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGxDQTl4LWLDR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy57NUC0N{DPxE1w	M2mwR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SN12C	M2HDWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NX\od3pvUW6qaXLpeIlwdiCxZjDoeY1idiCVTkGyR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy57NUW3N{DPxE1w	MnfxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
COR-L23	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NWT3WGR4UW6qaXLpeIlwdiCxZjDoeY1idiCFT2KtUFI{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|Lkm1OlY6KM7:TT6=	M2LHNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
VM-CUB-1	M3nSW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NE\vWXZKdmirYnn0bY9vKG:oIHj1cYFvKF[PLVPVRk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|Lkm2PVMyKM7:TT6=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
RXF393	M3TM[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHjY[olKdmirYnn0bY9vKG:oIHj1cYFvKFK[RkO5N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPC5yMUW5NUDPxE1w	NUHa[WE1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
MOLT-13	NWjmNHkyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFnwRphKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRwMEO0NVkh\|ryPLh?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
GCT	NH;qe5hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnHwTY5pcWKrdHnvckBw\iCqdX3hckBIS1RiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IESuNVA1PDJizszNMi=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SW1990	MoH3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2PDW2lvcGmkaYTpc44hd2ZiaIXtZY4hW1dzOUmwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1NjF4NkKyJO69VS5?	NUXXdGRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
RD	M4PrW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlTlTY5pcWKrdHnvckBw\iCqdX3hckBTTCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iND6xPVE{QCEQvF2u	NV62PYQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HOP-92	MlLPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NIfPfY9KdmirYnn0bY9vKG:oIHj1cYFvKEiRUD25NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPC5{MEC5N{DPxE1w	NVnkTW1sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
ME-180	M2fOSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWTJcohq[mm2aX;uJI9nKGi3bXHuJG1GNTF6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOE4zPTh3OTFOwG0v	MmnBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MZ7-mel	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MX\Jcohq[mm2aX;uJI9nKGi3bXHuJG1bPy2vZXygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvPDV{NkWg{txONg>?	NIm2dmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CAKI-1	NVXpR3Y4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{nhRmlvcGmkaYTpc44hd2ZiaIXtZY4hS0GNST2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1NjR4MEW3JO69VS5?	NELQSno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
YKG-1	NXTHUWNUT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVrJcohq[mm2aX;uJI9nKGi3bXHuJHlMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0MlU{PDJzIN88UU4>	M4fuRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
PANC-03-27	M4XpNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFHuPY5KdmirYnn0bY9vKG:oIHj1cYFvKFCDTlOtNFMuOjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IESuOVM6OjlizszNMi=>	NFv3RpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
A4-Fuk	M3HFZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NU\hdFJzUW6qaXLpeIlwdiCxZjDoeY1idiCDND3GeYsh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRwNUSyNFIh\|ryPLh?=	MlrOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NCI-H441	M{DVb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFrhepRKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOFQyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2LkW2N\|QzKM7:TT6=	M3qwRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
BxPC-3	MnHZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NV[4XpU6UW6qaXLpeIlwdiCxZjDoeY1idiCEeGDDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRwNkW5O\|Yh\|ryPLh?=	M324XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
ES3	NHHMcVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUTpVYdJUW6qaXLpeIlwdiCxZjDoeY1idiCHU{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvPjlzN{Og{txONg>?	M1HrV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
GP5d	NIW5VoZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mn3CTY5pcWKrdHnvckBw\iCqdX3hckBIWDWmIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0Mlc5PTV\|IN88UU4>	M3XEdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
CAL-85-1	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYHJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC16NT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1Njd7NEKg{txONg>?	NWT2XHp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
EPLC-272H	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHe3S41KdmirYnn0bY9vKG:oIHj1cYFvKEWSTFOtNlczUCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iND64NVY6QCEQvF2u	NFvRVoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HuP-T3	MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2\TfmlvcGmkaYTpc44hd2ZiaIXtZY4hUHWSLWSzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1Njh{NEC4JO69VS5?	Ml3NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SW1710	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MX3Jcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOU4xOzV2OTFOwG0v	M{mwZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
TE-8	M1zOXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mnn2TY5pcWKrdHnvckBw\iCqdX3hckBVTS16IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC1MlA3QTFzIN88UU4>	MlzhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
TE-12	NUjrN3BKT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M37YN2lvcGmkaYTpc44hd2ZiaIXtZY4hXEVvMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFUvOTN5MEOg{txONg>?	M4\Nd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H1573	NWjkUnNRT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NY\j[5hRUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE2PzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEWuNlczOzhizszNMi=>	NVnS[YEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SW1417	Ml\RS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NIPpOY9KdmirYnn0bY9vKG:oIHj1cYFvKFOZMUSxO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPS5{N{O5PEDPxE1w	M4T0OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
CHL-1	NWjHN4dJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4rw[mlvcGmkaYTpc44hd2ZiaIXtZY4hS0iOLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFUvOzF7OTFOwG0v	NIPSSVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
Calu-6	NGrQN2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3XtO2lvcGmkaYTpc44hd2ZiaIXtZY4hS2GudT22JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA2NjR{OUK3JO69VS5?	MorLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MDA-MB-231	MkPmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWi5[\|JsUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOjNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC1MlU3PTJ\|IN88UU4>	NGLCXIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SCC-25	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFXmZmlKdmirYnn0bY9vKG:oIHj1cYFvKFOFQz2yOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPS57N{GyNUDPxE1w	NWnzU4hNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
639-V	M4LDOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkLVTY5pcWKrdHnvckBw\iCqdX3hckA3OzlvVjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOk4yOjl\|MzFOwG0v	NYOxS2VPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
D-502MG	MlW4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGnZNIdKdmirYnn0bY9vKG:oIHj1cYFvKERvNUCyUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDZwMUe2OVkh\|ryPLh?=	M3y5SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
PANC-10-05	MnXqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHXRdGJKdmirYnn0bY9vKG:oIHj1cYFvKFCDTlOtNVAuODViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IE[uNlAyQDFizszNMi=>	MnHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	NXXlPZhIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MoLWTY5pcWKrdHnvckBw\iCqdX3hckBT[W2xcz2yS\|YuPENzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOk4zPzB7NDFOwG0v	MlP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NB10	MlzKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1rGW2lvcGmkaYTpc44hd2ZiaIXtZY4hVkJzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOk4{OjV\|MzFOwG0v	M2rHTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
MSTO-211H	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFzpWFlKdmirYnn0bY9vKG:oIHj1cYFvKE2VVF:tNlEyUCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNj60NFA5KM7:TT6=	NE\1OVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H1651	NFvYTGNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUfoXnU2UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3PTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IE[uOlU{OjhizszNMi=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
697	NF74[odIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHTNWXBKdmirYnn0bY9vKG:oIHj1cYFvKDZ7NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOk43PzN7NzFOwG0v	MnHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HCC70	NH20fY5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUfJcohq[mm2aX;uJI9nKGi3bXHuJGhESzdyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC2MlY5QDZ3IN88UU4>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SW1116	NY\qVGt{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWW1PYVpUW6qaXLpeIlwdiCxZjDoeY1idiCVV{GxNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDZwOEGyPVch\|ryPLh?=	M4e5bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SK-MES-1	MkTuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVrUNGN3UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSXMuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNj64OFg5KM7:TT6=	MmrxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
GCIY	MmG0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MUTJcohq[mm2aX;uJI9nKGi3bXHuJGdEUVliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IE[uPVE6PjJizszNMi=>	M1zQUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
GMS-10	NGLXRoJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3TUPGlvcGmkaYTpc44hd2ZiaIXtZY4hT02VLUGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA4NjB5N{W1JO69VS5?	NGPsV489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H1092	M1HQVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWHxOGk3UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFExQTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEeuNVU{OzRizszNMi=>	M1;wdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
CFPAC-1	NHfOVZJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEHkcYZKdmirYnn0bY9vKG:oIHj1cYFvKEOIUFHDMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDdwMkKxNFEh\|ryPLh?=	NXiw[npYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
TK10	NFfDSpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYrJcohq[mm2aX;uJI9nKGi3bXHuJHRMOTBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEeuN\|U2QDdizszNMi=>	M4P0e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
FADU	M4fPdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3nWeGlvcGmkaYTpc44hd2ZiaIXtZY4hTkGGVTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gO{42ODl\|IN88UU4>	M3vMdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
8305C	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1K1V2lvcGmkaYTpc44hd2ZiaIXtZY4hQDNyNVOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFcvQDV\|NUWg{txONg>?	NV;ZOWJVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
DK-MG	MoftS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mn7uTY5pcWKrdHnvckBw\iCqdX3hckBFUy2PRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gO{46PDl\|NzFOwG0v	MnHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
BFTC-909	NH21NYJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1zWOGlvcGmkaYTpc44hd2ZiaIXtZY4hSk[WQz25NFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDdwOUe4N\|Yh\|ryPLh?=	M2exblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
IGR-1	M4PxfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYjJcohq[mm2aX;uJI9nKGi3bXHuJGlIWi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC4MlE5ODVzIN88UU4>	M1:2N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
MDA-MB-361	MlLLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NIjIU5JKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0{PjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEiuNVgzPCEQvF2u	NIf2Vnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
KYSE-150	M162PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mn7NTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUG1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hQC5{MUmzO{DPxE1w	M4jNSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
DB	MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmDMTY5pcWKrdHnvckBw\iCqdX3hckBFSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iOD6zOlkxPSEQvF2u	NHfMdnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NH-12	NYLZOY5ET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mnf6TY5pcWKrdHnvckBw\iCqdX3hckBPUC1zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gPE41Ojd\|NjFOwG0v	NGHG[HM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CTV-1	MkDES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlO3TY5pcWKrdHnvckBw\iCqdX3hckBEXFZvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gPE41OzN\|NzFOwG0v	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
A498	MnvWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWjJcohq[mm2aX;uJI9nKGi3bXHuJGE1QThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEiuO\|g1PzVizszNMi=>	MkLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
LS-1034	NYm3[3RPT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnPMTY5pcWKrdHnvckBw\iCqdX3hckBNWy1zMEO0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA5Njl4NE[0JO69VS5?	M{nNUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
FTC-133	NITWV5ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVfJcohq[mm2aX;uJI9nKGi3bXHuJGZVSy1zM{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFgvQTh2NUmg{txONg>?	Moq1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
TGBC11TKB	NYH2PXh5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1zPOWlvcGmkaYTpc44hd2ZiaIXtZY4hXEeEQ{GxWGtDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB7LkGwPFM3KM7:TT6=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SK-MEL-1	NVLSRldlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NV33d3VRUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iOT6xPVE{PiEQvF2u	MnjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
RPMI-7951	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXK5UW5kUW6qaXLpeIlwdiCxZjDoeY1idiCUUF3JMVc6PTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEmuNlUzODFizszNMi=>	NWnP[44xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
GT3TKB	NFTuWXhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUDJcohq[mm2aX;uJI9nKGi3bXHuJGdVO1SNQjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gPU4{PzRyMzFOwG0v	MmDzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SW962	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXKx[HFzUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m2NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hQS53MkOyOUDPxE1w	M1PGblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
T-24	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4Pw[GlvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gPU43PThyNzFOwG0v	NHz4fmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
DBTRG-05MG	M3e3PWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NF;jSmVKdmirYnn0bY9vKG:oIHj1cYFvKESEVGLHMVA2VUdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEmuO\|U3PjZizszNMi=>	NG\CV2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
G-401	MkTlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NV3LXWhYUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTBwMEezPUDPxE1w	M3zRblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
RS4-11	M4\MO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4\MWmlvcGmkaYTpc44hd2ZiaIXtZY4hWlN2LUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOC5{N{mxJO69VS5?	MmrhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
KGN	NGOzb2VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NInFOHpKdmirYnn0bY9vKG:oIHj1cYFvKEuJTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVAvPDB2NjFOwG0v	NXnmbFFbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
786-0	NFrhW3hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVHNUFFkUW6qaXLpeIlwdiCxZjDoeY1idiB5OE[tNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTBwNEG2OkDPxE1w	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
EW-18	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NY\KS4dYUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTBwNEO2OkDPxE1w	NWLifo01RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
DEL	MnPyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVnlWlZyUW6qaXLpeIlwdiCxZjDoeY1idiCGRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFExNjV2NTFOwG0v	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HuH-7	NWjYT2VOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWXIXodEUW6qaXLpeIlwdiCxZjDoeY1idiCKdVitO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTBwNUewOUDPxE1w	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
MG-63	M1fk[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NV;GSo1xUW6qaXLpeIlwdiCxZjDoeY1idiCPRz22N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTBwN{OzN{DPxE1w	NEf3SGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
A253	NHTlZYpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYfxTno2UW6qaXLpeIlwdiCxZjDoeY1idiCDMkWzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOC55OUCyJO69VS5?	M4TrTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
TGW	M4naVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlT1TY5pcWKrdHnvckBw\iCqdX3hckBVT1diY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGwMlc6OzdizszNMi=>	NYKwPYFsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HH	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M17RW2lvcGmkaYTpc44hd2ZiaIXtZY4hUEhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGwMlgxPjJizszNMi=>	NGHm[Gg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
LS-411N	M{K5dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NV[zdpB[UW6qaXLpeIlwdiCxZjDoeY1idiCOUz20NVFPKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMD64NlQ1KM7:TT6=	MmrOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NCI-H2347	NGrUNFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml;HTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKzOFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFyLki0N\|ch\|ryPLh?=	M2rQPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
LU-65	MkLKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWjT[FJQUW6qaXLpeIlwdiCxZjDoeY1idiCOVT22OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTBwOUKyOkDPxE1w	NFj5[WY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
TE-11	NFjSS4xIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHz2bJhKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOS5yMkWg{txONg>?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SBC-1	MlLFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVPJcohq[mm2aX;uJI9nKGi3bXHuJHNDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNU4yODN{IN88UU4>	NYDQeYRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
TGBC24TKB	NUDsSJBYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Ml;RTY5pcWKrdHnvckBw\iCqdX3hckBVT0KFMkTUT2Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFzLkGxPEDPxE1w	NID4[lM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
ECC10	NFnMbpZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGVESzFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNU4zOjh\|IN88UU4>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
GR-ST	NYi5WZBFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVvJcohq[mm2aX;uJI9nKGi3bXHuJGdTNVOWIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNU4zPjhizszNMi=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H720	NV;RUFJMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFG4NmVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO\|IxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMT6zPVc4KM7:TT6=	Mn[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
VA-ES-BJ	MonsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{\rfmlvcGmkaYTpc44hd2ZiaIXtZY4hXkFvRWOtRmoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFzLkW1NVMh\|ryPLh?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
MOLT-16	NVPh[29FT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFHYU\|BKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF{LkGxOlEh\|ryPLh?=	M2f0T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
KYSE-140	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NETq[HlKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtNVQxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMj6xOVk3KM7:TT6=	NFTlWW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SCC-4	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NG\sb21KdmirYnn0bY9vKG:oIHj1cYFvKFOFQz20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOi5{NDFOwG0v	NUDleW1oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H1155	NILXVlhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYHFS\|VYUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFEyPTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGyMlMxOTdizszNMi=>	NUf4c5JzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
OCUB-M	M2j3eWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFrL[GRKdmirYnn0bY9vKG:oIHj1cYFvKE:FVVKtUUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTJwM{G4PUDPxE1w	NVvre217RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
MN-60	M3nVeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYPJcohq[mm2aX;uJI9nKGi3bXHuJG1PNTZyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNk4{PzN{IN88UU4>	M4fw[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
RO82-W-1	MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWPJcohq[mm2aX;uJI9nKGi3bXHuJHJQQDJvVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOi5\|OEe5JO69VS5?	M4rUXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
KOSC-2	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGtQW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVIvPTVyODFOwG0v	NHj5VYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
L-363	M3W2XWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIWzSoVKdmirYnn0bY9vKG:oIHj1cYFvKExvM{[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOi53OUK1JO69VS5?	NVnGWIFjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H661	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUPjcnY6UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFY3OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUKuPFU5PyEQvF2u	NIXpfYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
KYSE-450	M{D2Z2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlP2TY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUS1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTNwMEO5OkDPxE1w	M1rVb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
TI-73	NUTIboNHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUfJcohq[mm2aX;uJI9nKGi3bXHuJHRKNTd\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxN{4xPDRizszNMi=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
KNS-81-FD	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYLJcohq[mm2aX;uJI9nKGi3bXHuJGtPWy16MT3GSEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTNwMEe0PEDPxE1w	NGPESZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HCC1954	M2HFWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{XCb2lvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMUm1OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTNwMke4N{DPxE1w	NFnKOFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
A427	NUTN[mdjT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGzMlY3QDlizszNMi=>	MmDyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MOLT-4	M3v2bWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4C5R2lvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOy56NUOxJO69VS5?	Mne1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
U-118-MG	MlPjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXnn[XdrUW6qaXLpeIlwdiCxZjDoeY1idiCXLUGxPE1OTyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUOuPFcxOiEQvF2u	MmPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SF126	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{XVS2lvcGmkaYTpc44hd2ZiaIXtZY4hW0ZzMk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE{NjlzNkWg{txONg>?	NHTSW2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SF539	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NH3sN5NKdmirYnn0bY9vKG:oIHj1cYFvKFOINUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOy57NEe0JO69VS5?	MmfQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
Daoy	NI\SUI5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4Hm[mlvcGmkaYTpc44hd2ZiaIXtZY4hTGGxeTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVQvPDl5OTFOwG0v	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
DoTc2-4510	NGrNbYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1PJZmlvcGmkaYTpc44hd2ZiaIXtZY4hTG:WY{KtOFUyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUSuOVE4PSEQvF2u	NIDRXVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
TYK-nu	NIi2cZhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYDJcohq[mm2aX;uJI9nKGi3bXHuJHR[Uy2wdTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVQvPTZizszNMi=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
CGTH-W-1	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NIjpTW5KdmirYnn0bY9vKG:oIHj1cYFvKEOJVFitW{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzND64OFg{KM7:TT6=	NWDyPZZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HuO9	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NELCTI1KdmirYnn0bY9vKG:oIHj1cYFvKEi3T{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE2NjB4MzFOwG0v	MmrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
EW-16	NHS2eYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXvJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxOU4xQTR7IN88UU4>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H630	NVHYXWVUT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mo\TTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSE[zNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTVwMU[xN{DPxE1w	NIXwN2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CAL-12T	NEDHO\|FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NF3MXFBKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2xNnQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF3LkOzNUDPxE1w	NF75enk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
TE-5	MkPiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NY[2N2xoUW6qaXLpeIlwdiCxZjDoeY1idiCWRT21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyPS54MUOzJO69VS5?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
U251	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NX3HdXNqUW6qaXLpeIlwdiCxZjDoeY1idiCXMkWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyPS55M{izJO69VS5?	M3HmXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
BB49-HNC	NGrL[m9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1H4[WlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ2OT3IUmMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF4LkWwOkDPxE1w	NWHRW\|h5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
OCI-AML2	M{naTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWDCcoV5UW6qaXLpeIlwdiCxZjDoeY1idiCRQ1mtRW1NOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMU[uOlY2KM7:TT6=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
KINGS-1	NHu3cpNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3\RR2lvcGmkaYTpc44hd2ZiaIXtZY4hU0mQR2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTZwNkmxPEDPxE1w	MnPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
D-566MG	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWDJcohq[mm2aX;uJI9nKGi3bXHuJGQuPTZ4TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE3Njd{NkKg{txONg>?	NWOzWmNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
P30-OHK	NH7zV2dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJHA{OC2RSFugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE3NjlyNkig{txONg>?	MoDYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
GAMG	NGjmbmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWnpUI1NUW6qaXLpeIlwdiCxZjDoeY1idiCJQV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyPi57MkSzJO69VS5?	NXXLbWRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HCC1419	NX;ZO4tIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHnzUZRKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{G0NVkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF5Lk[xN\|kh\|ryPLh?=	NWDtSFhbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SNU-C2B	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWrJcohq[mm2aX;uJI9nKGi3bXHuJHNPXS2FMlKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE4Njd\|N{eg{txONg>?	MlPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MHH-NB-11	M4HtdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlfYTY5pcWKrdHnvckBw\iCqdX3hckBOUEhvTlKtNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF6LkGzPFMh\|ryPLh?=	Moq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
COLO-684	Mo\sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGe4UW5KdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tOlg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzOD6yN\|g{KM7:TT6=	NXXCRnltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
OC-314	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NX;0PJpiUW6qaXLpeIlwdiCxZjDoeY1idiCRQz2zNVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF6LkO1PEDPxE1w	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
Becker	NXrTU4hUT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEPPfW1KdmirYnn0bY9vKG:oIHj1cYFvKEKnY3vldkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOThwNE[yN{DPxE1w	NXPlbVJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H1623	NGXJe2NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NIi4b5RKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVYzOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUiuOlM3QCEQvF2u	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
IGROV-1	MmjYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnGwTY5pcWKrdHnvckBw\iCqdX3hckBKT1KRVj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyQC54NUW5JO69VS5?	MoftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HSC-2	NVTFd\|U{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUTJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxPE46PTd5IN88UU4>	MlfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
RMG-I	M1j5UGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MX;Jcohq[mm2aX;uJI9nKGi3bXHuJHJOTy2LIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxPU4yOzN6IN88UU4>	M1HWUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
CAL-120	M3zldGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXnJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1zMkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE6NjJ\|NUSg{txONg>?	M33RflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
GB-1	NGrUephIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUja[HB4UW6qaXLpeIlwdiCxZjDoeY1idiCJQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyQS55NES0JO69VS5?	M3nqdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
LU-139	NWS5SIU1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVTP[o5UUW6qaXLpeIlwdiCxZjDoeY1idiCOVT2xN\|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJyLkG4NVYh\|ryPLh?=	NHjZSZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HT-1376	NUT3VG1OT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWPh[lROUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xN\|c3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{MD61O\|czKM7:TT6=	NV72[o1{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SW982	NWT0TZB3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVvxTHppUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjBwNkizO{DPxE1w	M4nW[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SK-N-FI	M1;GNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVfpfGxtUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OMWZKKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{MT6wPFg3KM7:TT6=	NInnU3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SCC-9	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlT2TY5pcWKrdHnvckBw\iCqdX3hckBUS0NvOTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlEvOTRyOTFOwG0v	NX3yTXF{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SW756	MlruS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGrOclNKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{W2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOS5{MUW2JO69VS5?	NXHae3Q4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SW948	NI\6e\|BIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnLQTY5pcWKrdHnvckBw\iCqdX3hckBUXzl2ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlEvPTJ\|NjFOwG0v	NUP2[GJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SW1573	M1nlTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4L2[2lvcGmkaYTpc44hd2ZiaIXtZY4hW1dzNUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOS56M{S1JO69VS5?	MnLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NCI-H1792	NHfsXGlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NV70WJZWUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4QTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEKxMlg2PjVizszNMi=>	M4The\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
BE-13	NXeyXWJ2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIjxTIdKdmirYnn0bY9vKG:oIHj1cYFvKEKHLUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOi53OEezJO69VS5?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SK-OV-3	MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUfJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU:YLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIzNjd\|OEig{txONg>?	MlTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
PA-1	M4PBXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1Hme2lvcGmkaYTpc44hd2ZiaIXtZY4hWEFvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlIvQDdzMjFOwG0v	NES2dYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H1693	NX;Benp2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMU[5N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjJwOUOxN{DPxE1w	Mm\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
no-10	M1OybGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWPJcohq[mm2aX;uJI9nKGi3bXHuJI5wNTFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyN{4{PTh6IN88UU4>	NF76[Fc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
JVM-2	NXTnbol[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mlz4TY5pcWKrdHnvckBw\iCqdX3hckBLXk1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlMvPDF2NzFOwG0v	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SK-NEP-1	MmLwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEm0UGdKdmirYnn0bY9vKG:oIHj1cYFvKFONLV7FVE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{Mz61NlA2KM7:TT6=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
PC-3	NWXoToNOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3HEcGlvcGmkaYTpc44hd2ZiaIXtZY4hWENvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlMvPTd{MjFOwG0v	MnTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
U-2-OS	NXPRbpM3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1j5bmlvcGmkaYTpc44hd2ZiaIXtZY4hXS1{LV;TJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOy56NE[5JO69VS5?	MlmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NBsusSR	NVPBSIt[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIL6XJpKdmirYnn0bY9vKG:oIHj1cYFvKE6Ec4XzV3Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ2LkGwOlIh\|ryPLh?=	NEDwPI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
EW-13	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1nKbWlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI1NjF\|OUig{txONg>?	NX20OlY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
BT-20	MnTCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVnJcohq[mm2aX;uJI9nKGi3bXHuJGJVNTJyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyOE44OTd6IN88UU4>	MmrwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MS-1	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoHoTY5pcWKrdHnvckBw\iCqdX3hckBOWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyOU4xPDl6IN88UU4>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HCC1187	Mo\uS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4nLWWlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMUG4O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjVwNES1NUDPxE1w	M1fLcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
TE-1	MofvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVPJcohq[mm2aX;uJI9nKGi3bXHuJHRGNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEK1MlY6PTNizszNMi=>	MmLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MKN7	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Moe4TY5pcWKrdHnvckBw\iCqdX3hckBOU055IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyOU44QTF\|IN88UU4>	M17rPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H727	NEf6SGRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHXtc5NKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO\|I4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{Nj6wOVE{KM7:TT6=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
H4	MkTzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NF70fXZKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyOk4{PzZ6IN88UU4>	NWqzSIt[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
647-V	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NWjwSZFWUW6qaXLpeIlwdiCxZjDoeY1idiB4NEetWkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjZwOEixNUDPxE1w	M3fkdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
KM-H2	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmGyTY5pcWKrdHnvckBw\iCqdX3hckBMVS2KMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlYvQTJ2IN88UU4>	M{PFXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
ABC-1	MlfCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3mxRWlvcGmkaYTpc44hd2ZiaIXtZY4hSUKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI4NjF7N{Sg{txONg>?	NVvNbpBPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HCC1806	MnPHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYPJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF6ME[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI4NjN2MkKg{txONg>?	M4rVb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
ES5	NGi3[FNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXLGVWN2UW6qaXLpeIlwdiCxZjDoeY1idiCHU{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI4NjR7OUmg{txONg>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
C3A	NVzyUI1vT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlzhTY5pcWKrdHnvckBw\iCqdX3hckBEO0FiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEK3MlU3QTRizszNMi=>	M{fDeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
TE-10	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUfJcohq[mm2aX;uJI9nKGi3bXHuJHRGNTFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyO{43OzV4IN88UU4>	Ml;WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
S-117	Mn\aS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEHlW2lKdmirYnn0bY9vKG:oIHj1cYFvKFNvMUG3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzPy55NUexJO69VS5?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
TGBC1TKB	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUjJcohq[mm2aX;uJI9nKGi3bXHuJHRISkNzVFvCJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzPy57OUCyJO69VS5?	NXjobWp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H1793	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnXYTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3PVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ6LkOwO\|Yh\|ryPLh?=	NWnaV2pURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
ES4	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2TD[GlvcGmkaYTpc44hd2ZiaIXtZY4hTVN2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyPE44OzV{IN88UU4>	M2Px[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
AN3-CA	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmHOTY5pcWKrdHnvckBw\iCqdX3hckBCVjNvQ1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI5Njh3OUOg{txONg>?	NGKzZWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NMC-G1	NWXMW3VrT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NH20TZpKdmirYnn0bY9vKG:oIHj1cYFvKE6PQz3HNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjlwMUGxJO69VS5?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H226	NEW5ZZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGTCWHpKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlI3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{OT6yO\|AyKM7:TT6=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H522	NVz1TpQzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MkH3TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEWyNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjlwOEOzPUDPxE1w	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SW48	NIXrXZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M{Pp[mlvcGmkaYTpc44hd2ZiaIXtZY4hW1d2ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlkvQTJ3MjFOwG0v	NG\NUlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
OE33	MkPOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MUXJcohq[mm2aX;uJI9nKGi3bXHuJG9GOzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEOwMlc6PTRizszNMi=>	MnrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NCI-H2228	MoXTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NUjYWJpVUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIzOjhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEOxMlA{PDRizszNMi=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
D-423MG	MmfRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXXJcohq[mm2aX;uJI9nKGi3bXHuJGQuPDJ\|TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFMyNjB3NkSg{txONg>?	M3;RdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
IST-MEL1	M17TcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYrJcohq[mm2aX;uJI9nKGi3bXHuJGlUXC2PRVyxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{OS5zNUK4JO69VS5?	Ml\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
A388	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmSyTY5pcWKrdHnvckBw\iCqdX3hckBCOzh6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzNU43OjN4IN88UU4>	Ml[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
LN-405	M3i3dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{f1TGlvcGmkaYTpc44hd2ZiaIXtZY4hVE5vNEC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{OS55OUizJO69VS5?	M3fL[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
DMS-273	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVzJcohq[mm2aX;uJI9nKGi3bXHuJGROWy1{N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFMyNjlzM{ig{txONg>?	NHvvVJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
KS-1	NVTOSIxlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M13zNmlvcGmkaYTpc44hd2ZiaIXtZY4hU1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|MvOTN{MTFOwG0v	NVT1[FV2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H209	M17Xemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MY\Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkC5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{Oy52NUG3JO69VS5?	NIX0UpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HOS	NEGwUYNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWnOWW9NUW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFM{Njd{NUOg{txONg>?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
GI-1	M13JUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkfuTY5pcWKrdHnvckBw\iCqdX3hckBIUS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzN{45ODdzIN88UU4>	MkTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
RERF-LC-MS	MoizS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVvJcohq[mm2aX;uJI9nKGi3bXHuJHJGWkZvTFOtUXMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN2LkCzNVUh\|ryPLh?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H526	MnH0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{D1d2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NlYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN2LkC3OkDPxE1w	NWX6e5c5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
RPMI-2650	M1zCeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWfJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvMk[1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzRwNEOzOEDPxE1w	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
KYSE-70	NHTPUIdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkXnTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUewJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{PC56NEK2JO69VS5?	NGLJR2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
Capan-2	M2LpRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1fHO2lvcGmkaYTpc44hd2ZiaIXtZY4hS2GyYX6tNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzZwNE[1NkDPxE1w	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
OVCAR-4	NIHxU3BIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnzBTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{Py5{MUe2JO69VS5?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
OVCAR-8	NGflNWlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3ftSmlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzdwOUiyN{DPxE1w	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H1355	MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3XWW2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixN\|U2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|OD6xNFUyKM7:TT6=	NX\PWnhFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
COLO-680N	NHfUNZRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXPJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNkiwUkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzhwMkSyPUDPxE1w	M2H5TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H2122	NEjO[XJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M13SOmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|OT6zN\|Y{KM7:TT6=	M2DzSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
Saos-2	MlzWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MUfJcohq[mm2aX;uJI9nKGi3bXHuJHNid3NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|kvPzB3MzFOwG0v	MlfZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HCC2157	M2rVd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUjpUWxsUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OyNVU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2MD63O\|M1KM7:TT6=	M1vrVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
VMRC-RCZ	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUDJcohq[mm2aX;uJI9nKGi3bXHuJHZOWkNvUlPaJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1OS5{OU[yJO69VS5?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
ETK-1	NELQPVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWDXS\|JEUW6qaXLpeIlwdiCxZjDoeY1idiCHVFutNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDFwNUe1NUDPxE1w	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
RCC10RGB	MkPNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NF;1RYZKdmirYnn0bY9vKG:oIHj1cYFvKFKFQ{GwVmdDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2Mj6wNVgh\|ryPLh?=	M2fQNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
KP-N-YS	NFL4NHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXHJcohq[mm2aX;uJI9nKGi3bXHuJGtRNU5vWWOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQzNjB4NEGg{txONg>?	M{HVdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
T98G	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGfVR4FKdmirYnn0bY9vKG:oIHj1cYFvKFR7OFegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQzNjZ5M{Og{txONg>?	NETsU4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
A431	MnPGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlzoTY5pcWKrdHnvckBw\iCqdX3hckBCPDNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0OU4yQDNzIN88UU4>	M2n6TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HDLM-2	NF;DUG9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4HmcGlvcGmkaYTpc44hd2ZiaIXtZY4hUESOTT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1PS5{NkG3JO69VS5?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
CHP-134	NVrEOYpvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M2TEW2lvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUGzOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDZwMUe3PUDPxE1w	Ml[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
J-RT3-T3-5	NIn6OmNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnPpTY5pcWKrdHnvckBw\iCqdX3hckBLNVKWMz3UN{02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2Nj60OFYyKM7:TT6=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H1650	M4rPSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHjNboNKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNE[uOVExPCEQvF2u	NUC3PIRmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
MHH-PREB-1	Ml;WS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mke0TY5pcWKrdHnvckBw\iCqdX3hckBOUEhvUGLFRk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2Nj61NlY3KM7:TT6=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SJRH30	NFXqbodIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NF7PRXRKdmirYnn0bY9vKG:oIHj1cYFvKFOMUlizNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDZwN{e3OUDPxE1w	NWDMO3J[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SF295	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlPkTY5pcWKrdHnvckBw\iCqdX3hckBUTjJ7NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFgvPTF7IN88UU4>	NVS4VYdFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
YAPC	NFzrTGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MY\Jcohq[mm2aX;uJI9nKGi3bXHuJHlCWENiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IES4Mlk1OiEQvF2u	M2TnUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
EFM-19	NX:wPFBZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M17zRWlvcGmkaYTpc44hd2ZiaIXtZY4hTU[PLUG5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1QS53MEi1JO69VS5?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
MIAPaCa2	MmjqVJJwdGmoZYLheIlwdiCjc4PhfS=>		NFHFPFBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3JRXBiS2F{IHPlcIx{NCCLQ{WwQVE1OiCwTT6=	NGDWVng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S3OFM5QCd-MkO0O\|Q{QDh:L3G+
A375	MVfQdo9tcW[ncnH0bY9vKGG\|c3H5	NWG1T5FqPzJiaB?=	NWjpN\|F2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN\|c2KGOnbHzzJIV5eHKnc4PpcochSlKDRjDWOlAxTSCvdYThcpQh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGxidHn0[ZIu\2yxIHHzd4F6NCCLQ{WwQVMyKG6PLh?=	NFL5Uog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S3OFM5QCd-MkO0O\|Q{QDh:L3G+
A549	NEXKe3ZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M4HtW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczygTWM2OCB;IEGuO\|Uh\|ryPLh?=	MmLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2N{SzPFgoRjJ\|NEe0N\|g5RC:jPh?=
LoVo	NXm1PGhHSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NWnCfJVwSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMc3ZwKGOnbHzzMEBKSzVyIE2gNk45OyEQvF2u	M3zRPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEe0N\|g5Lz5{M{S3OFM5QDxxYU6=
HCT116	NV7sOG1ISW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVLjT4tuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh\XiycnXzd4lv\yCNUlHTJGcyO0RibYX0ZY51NCCLQ{WwJF0hOy5zIN88UU4>	NWew[2EzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0O\|Q{QDhpPkKzOFc1Ozh6PD;hQi=>
HeLa-MaTu	MXHGeY5kfGmxbjDhd5NigQ>?		MXnJcohq[mm2aX;uJI9nKE2HS{GgbY4hcHWvYX6gTIVN[S2PYWT1JI1ifGOqZXSgdIFqeiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gSXJMKHCqb4PwbI9zgWyjdHnvckwhUUN3MDC9JFAvODF2IN88UU4>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZzMUmyNEc,OjZ4MUG5NlA9N2F-
HepG2	NEi2NIFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NV\aPVZMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bp[XKkb4LpcochVi2UYYOgcZV1[XSrb36sJGlEPTBiPTCwMlA{OiEQvF2u	NWPrUXdvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2NVE6OjBpPkK2OlEyQTJyPD;hQi=>
COLO205	NIXkb5dCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M4OzUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1;MU\|IxPSClZXzsd{Bp[XKkb4LpcochSlKDRjDteZRifGmxbjygTWM2OCB;IECuNFY6KM7:TT6=	NWDnTVRsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2NVE6OjBpPkK2OlEyQTJyPD;hQi=>
A549	MoWyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MoLrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHjhdoJwemmwZzDLMXJieyCvdYTheIlwdixiSVO1NEA:KDFwN{Wg{txONg>?	NYGwVWc1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2NVE6OjBpPkK2OlEyQTJyPD;hQi=>
HCT116	NXz5UJJbSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1:1fWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIhiemKxcnnu[{BMNVKjczDHNVNFKG23dHH0bY9vNCCLQ{WwJF0hOyEQvF2u	NHvFV\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[xNVkzOCd-Mk[2NVE6OjB:L3G+
HeLa-MaTu-ADR	MVLGeY5kfGmxbjDhd5NigQ>?		NV\VVoFXUW6qaXLpeIlwdiCxZjDNSWsyKGmwIHj1cYFvKEinTHGtUYFVfS2DRGKgcYF1[2inZDDwZYlzKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDFVmsheGixc4Doc5J6dGG2aX;uMEBKSzVyIE2gN{44KM7:TT6=	MmDhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4MUG5NlAoRjJ4NkGxPVIxRC:jPh?=
SW480	NVnxSG5YSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=	MoXXO\|IhcHK\|	MmPrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVV{S4NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD60NlIh\|ryPLh?=	NED3[\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{S0PFkyQCd-Mke0OFg6OTh:L3G+
SW620	MmDqRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	NUfLcGs2PzJiaILz	MnLVRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVV{[yNEBk\WyuczDoZZJjd3KrbnegT3JCWyCJMULWJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IECuNFE2KM7:TT6=	NFi0Rmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OECzPFk1OCd-MkiwN\|g6PDB:L3G+
AsPC1	M3m1bWFvfGmycn;sbYZmemG2aY\lJIF{e2G7	MVi3NkBpenN?	M1XpdWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQYPQR\|Eh[2WubIOgbIFz[m:{aX7nJGtTSVNiR{GySEBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGlEPTBiPTCwMlA3PDJizszNMi=>	NWXQOG1nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwN\|g6PDBpPkK4NFM5QTRyPD;hQi=>
BA/F3	MUTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	NUn1PIYxPzJiaILz	NYfMNlVuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{Bp[XKkb4LpcochU1KDUzDHNVJFKG23dHHueEBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFAvOSEQvF2u	NVi4[WFsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwN\|g6PDBpPkK4NFM5QTRyPD;hQi=>
SKCO1	NWHpfYxPSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=	MkjIO\|IhcHK\|	NX\FUpdDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT2NQOSClZXzsd{Bp[XKkb4LpcochU1KDUzDHNVJXKG23dHHueEBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFAvOTF5IN88UU4>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB\|OEm0NEc,OjhyM{i5OFA9N2F-
COLO205	NHH3UmpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	NIHPUlg4OiCqcoO=	NETicnJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPPUG8zODViY3XscJMhcGG{Yn;ybY5oKEKUQV[gcZV1[W62L4fpcIQhfHmyZTDLVmFUN3erbHSgeJlx\SCSSVuzR2Eh[W[2ZYKgO\|IhcHK\|IHL5JGNEUzhiYYPzZZktKEmFNUCgQUAxNjB3OTFOwG0v	NUPldINDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzNVcyPDhpPkK5N\|E4OTR6PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK / ERK / β-catenin / E-cadherin / Vimentin / Fibronection; PubMed: 26384399 Mol Cancer Ther MDA-MB-231 and SUM149 cells were treated with selumetinib for 48 hours, and western blot analysis was performed, with β-actin used as a loading control. pS6(235/236) / pS6(240/244); PubMed: 26137449 Mol Cancer Ther Selumetinib (Sel) in combination with BEZ235 or ZSTK474 inhibits pS6 expression in BRAF-mutant melanoma cell lines that are highly sensitive (NZM3, NZM11, NZM20) or moderately sensitive (NZM6, NZM7, NZM12) to single agent selumetinib. Cells were treated with 500 nM of each compound as indicated for 1 or 24 h. Blots are representative images of two independent determinations. pVEGFR(Y1175) / VEGFR2 / pPDGFRβ(Y751) / pPDGFRβ / pAXL(Y702) / AXL / pMEK / MEK; PubMed: 22500798 Cell Dose-dependent RTK reprogramming in response to AZD6244. Dose-dependent induction of RTK expression and activity in 24h-treated SUM159 cells was determined by western blot. Bak / Bad / Bcl-xl / BimEL / BimL / BimS / PUMA / NOXA ; PubMed: 20885957 PLoS One Human lung cancer cell lines (Calu-6, H2347, and H3122) were treated with 3 µM AZD6244 for 4, 8, 24, 48, and 72 hours. Western blots of Bcl-2 family members after treatment with AZD6244.	26384399 26137449 22500798 20885957
Immunofluorescence	β-catenin; PubMed: 26384399 Mol Cancer Ther MDA-MB-231 and SUM149 cells were treated with selumetinib in a 3D culture for 48 hours. Immunofluorescence staining was done to detect β-catenin-FITC (fluorescein isothiocyanate), and nuclei were stained with DAPI. Images were taken under 60× magnification. FOXO3a; PubMed: 20885957 PLoS One Subcellular localization of FOXO3a in Calu-6 and H522 cells was detected with immunofluorescence staining after AZD6244 treatment.	26384399 20885957
Growth inhibition assay	Cell viability; PubMed: 26384399 Mol Cancer Ther MDA-MB-231 and SUM149 cells were treated with selumetinib for 72 hours, and then cell viability was measured using the WST-1 assay.	26384399

In vivo

AZD6244 significantly inhibits phosphorylation of ERK1/2 in 2-1318, 5-1318, 26-1004 and 4-1318 xenografts and induces apoptosis in primary 2-1318 cells by activating the caspase pathway. ^[1] AZD6244 could inhibit the tumor growth in HT-29 xenograft, which is a colorectal tumor model carrying a B-Raf mutation, at a dose of 100 mg/kg and the tumor growth inhibition of AZD6244 is better than it of Gemcitabine. ^[3] Otherwise AZD6244 could inhibit HCC xenografts tumor growth, which associated with increased apoptosis and down-regulation of cell cycle regulators, including cyclin D1, Cdc-2, CDK2 and 4, cyclin B1, and c-Myc. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Assay of MEK Kinase Activity: Anti-MEK1 antibody is used to immunoprecipitate MEK1 molecules. MEK kinase activity is measured as the ability of immuno-isolated MEK1 to activate recombinant ERK1 in a coupled assay using MBP as the end point of the assay. Phosphorylated MBP is resolved on a 14% SDS-PAGE gel and vacuum-dried before exposure to X-ray film.
Cell Research: ^[1]	- Collapse Cell lines: Primary HCC cell lines including 2-1318, 4-1318 and 26-1004 cells Concentrations: ~ 10 μM Incubation Time: 24 or 48 hours Method: Cells are seeded at a density of 2.0 × 10⁴. After 48 hours incubation, the cells are rinsed twice with culture media. Cells are treated with various concentrations of AZD6244 for 24 or 48 hours. Cell viability is determined by the 3-(4,5-dimethylthiazol-2y1)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell proliferation is assayed using a bromodeoxyuridine kit. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: HCC xenografts in mice homozygous for the SCID (severe combined immunodeficiency) mutation Dosages: 50 or 100mg/kg Administration: Administered via p.o. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	91 mg/mL warmed (198.82 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Selumetinib (AZD6244) SDF

Molecular Weight	457.68
Formula	C₁₇H₁₅BrClFN₄O₃
CAS No.	606143-52-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	ARRY-142886
Smiles	CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04590235	Not yet recruiting	Drug: Selumetinib	Neurofibromatosis 1\|Neurofibroma Plexiform	AstraZeneca\|Merck Sharp & Dohme Corp.	November 12 2020	Phase 1
NCT03433183	Recruiting	Drug: Selumetinib\|Drug: Sirolimus	Malignant Peripheral Nerve Sheath Tumors\|Neurofibromatosis 1	Sarcoma Alliance for Research through Collaboration\|United States Department of Defense\|AstraZeneca	October 2 2019	Phase 2
NCT03326388	Recruiting	Drug: Selumetinib	Neurofibromatosis Type 1\|Plexiform Neurofibroma\|Optic Nerve Glioma	Great Ormond Street Hospital for Children NHS Foundation Trust\|AstraZeneca	September 26 2019	Phase 1\|Phase 2
NCT03833427	Active not recruiting	Drug: Selumetinib\|Biological: Pembrolizumab	Advanced/Metastatic Solid Tumors	Merck Sharp & Dohme Corp.	March 18 2019	Phase 1
NCT03745989	Active not recruiting	Drug: MK-8353\|Drug: Selumetinib	Solid Tumors	Merck Sharp & Dohme Corp.	February 22 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How about the solubility of S1008? How to prepare for the solution if I need to do the in vivo experiments?
Answer:
S1008 AZD6244 in vehicle 5% DMSO+30% PEG 300+ddH2O will be a suspension for oral administration. If you want a clear solution for injection, you can dissolve it in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Pan MEK Inhibitor

U0126-EtOH : MEK1, IC50=0.07 μM; MEK2, IC50=0.06 μM,
Most Potent MEK Inhibitor

PD0325901 : MEK, IC50=0.33 nM,
FDA-approved MEK Inhibitor

Trametinib (GSK1120212) : Approved by FDA for BRAF V600E mutated metastatic melanoma.
Newest MEK Inhibitor

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.

Related MEK Products

Cobimetinib (GDC-0973) ^New

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Cobimetinib induces apoptosis. Phase 3.
BI-847325 ^New

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
GDC-0623 ^New

GDC-0623 (G-868) is a potent and ATP-uncompetitive MEK1 inhibitor with K_i of 0.13 nM. Phase 1.
Trametinib (GSK1120212)

Trametinib (GSK1120212, JTP-74057, Mekinist) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. Trametinib activates autophagy and induces apoptosis.

Features:More potent than PD0325901 or AZD6244.
Mirdametinib (PD0325901)

Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
U0126-EtOH

U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059. U0126 inhibits autophagy and mitophagy with antiviral activity.

Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.
PD98059

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR) and functions as an AHR antagonist.

Features:Does not inhibit c-Raf phosphorylated MEK1.
PD184352 (CI-1040)

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. PD184352 (CI-1040) selectively induces apoptosis. Phase 2.

Features:First MEK inhibitor to begin clinical development.
Binimetinib (MEK162)

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Binimetinib induces G1 cell cycle arrest and apoptosis in human NSCLC cell lines and induces autophagy. Phase 3.
Refametinib (RDEA119)

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

Selumetinib (AZD6244)